These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 20714913

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of factors associated with the achievement of an optimal teicoplanin trough concentration
.
    Takechi K, Yanagawa H, Zamami Y, Ishizawa K, Tanaka A, Araki H.
    Int J Clin Pharmacol Ther; 2017 Aug; 55(8):672-677. PubMed ID: 28655381
    [Abstract] [Full Text] [Related]

  • 5. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level.
    Sato M, Chida K, Suda T, Muramatsu H, Suzuki Y, Hashimoto H, Gemma H, Nakamura H.
    J Infect Chemother; 2006 Aug; 12(4):185-9. PubMed ID: 16944256
    [Abstract] [Full Text] [Related]

  • 6. Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection.
    Ogawa R, Kobayashi S, Sasaki Y, Makimura M, Echizen H.
    Int J Clin Pharmacol Ther; 2013 May; 51(5):357-66. PubMed ID: 23458228
    [Abstract] [Full Text] [Related]

  • 7. Development of initial loading procedure for teicoplanin in critically ill patients with severe infections.
    Matsumoto K, Kanazawa N, Watanabe E, Yokoyama Y, Fukamizu T, Shimodozono Y, Maeda C, Yasuda T, Kakihana Y, Ikawa K, Morikawa N, Takeda Y.
    Biol Pharm Bull; 2013 May; 36(6):1024-6. PubMed ID: 23727923
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dosing vancomycin in the super obese: less is more.
    Crass RL, Dunn R, Hong J, Krop LC, Pai MP.
    J Antimicrob Chemother; 2018 Nov 01; 73(11):3081-3086. PubMed ID: 30203073
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S, Tsuji Y, Mizoguchi A, Kasai H, Ishibashi T, Iwamura N, To H.
    J Clin Pharm Ther; 2016 Aug 01; 41(4):399-402. PubMed ID: 27144370
    [Abstract] [Full Text] [Related]

  • 12. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days.
    Ueda T, Takesue Y, Nakajima K, Ichiki K, Ishikawa K, Takai Y, Yamada K, Tsuchida T, Otani N, Takahashi Y, Ishihara M, Takubo S, Ikeuchi H, Uchino M, Kimura T.
    BMC Pharmacol Toxicol; 2020 Jul 08; 21(1):50. PubMed ID: 32641110
    [Abstract] [Full Text] [Related]

  • 13. Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics.
    Niwa T, Imanishi Y, Ohmori T, Matsuura K, Murakami N, Itoh Y.
    Int J Antimicrob Agents; 2010 May 08; 35(5):507-10. PubMed ID: 20185275
    [Abstract] [Full Text] [Related]

  • 14. Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia.
    Garazzino S, Aprato A, Baietto L, D'Avolio A, Maiello A, De Rosa FG, Aloj D, Siccardi M, Biasibetti A, Massè A, Di Perri G.
    Clin Pharmacokinet; 2008 May 08; 47(12):793-805. PubMed ID: 19026035
    [Abstract] [Full Text] [Related]

  • 15. Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.
    Meng L, Wong T, Huang S, Mui E, Nguyen V, Espinosa G, Desai J, Holubar M, Deresinski S.
    Pharmacotherapy; 2019 Apr 08; 39(4):433-442. PubMed ID: 30739349
    [Abstract] [Full Text] [Related]

  • 16. High-dose regimen to achieve novel target trough concentration in teicoplanin.
    Ueda T, Takesue Y, Nakajima K, Ichki K, Wada Y, Komatsu M, Tsuchida T, Takahashi Y, Ishihara M, Kimura T, Uchino M, Ikeuchi H.
    J Infect Chemother; 2014 Jan 08; 20(1):43-7. PubMed ID: 24462424
    [Abstract] [Full Text] [Related]

  • 17. The use and therapeutic drug monitoring of teicoplanin in the UK.
    Darley ES, MacGowan AP.
    Clin Microbiol Infect; 2004 Jan 08; 10(1):62-9. PubMed ID: 14706088
    [Abstract] [Full Text] [Related]

  • 18. Population pharmacokinetics of teicoplanin in children.
    Ramos-Martín V, Paulus S, Siner S, Scott E, Padmore K, Newland P, Drew RJ, Felton TW, Docobo-Pérez F, Pizer B, Pea F, Peak M, Turner MA, Beresford MW, Hope WW.
    Antimicrob Agents Chemother; 2014 Nov 08; 58(11):6920-7. PubMed ID: 25224001
    [Abstract] [Full Text] [Related]

  • 19. Innovative approaches to optimizing the delivery of vancomycin in individual patients.
    Pai MP, Neely M, Rodvold KA, Lodise TP.
    Adv Drug Deliv Rev; 2014 Nov 20; 77():50-7. PubMed ID: 24910345
    [Abstract] [Full Text] [Related]

  • 20. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients.
    Pea F, Furlanut M, Negri C, Pavan F, Crapis M, Cristini F, Viale P.
    Antimicrob Agents Chemother; 2009 May 20; 53(5):1863-7. PubMed ID: 19223642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.